ATOS
Atossa Therapeutics, Inc.
There isn't enough reported data to score ATOS yet.
ATOS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ATOS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ATOS PE Valuation
ATOS has no meaningful PE right now: it lost money over the past year.
ATOS Forward outlook
There aren't enough analyst estimates for ATOS to show an outlook.
ATOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.81 | -$0.36 |
| Q2 2026 | -$4.30 | -$1.00 |
| Q1 2026 | -$4.40 | -$1.40 |
| Q4 2025 | -$4.04 | -$1.04 |
| Q3 2025 | -$3.45 | -$0.15 |
| Q2 2025 | -$3.30 | -$0.15 |
| Q1 2025 | -$3.00 | +$0.60 |
| Q4 2024 | -$3.00 | +$0.60 |
ATOS is still losing money, but far less than before: $3.81 per share over the past year, against $30.45 at its worst in late 2019.
ATOS Quarterly Revenue
ATOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | +$492K |
| Q2 2026 | -$9.6M | -$2.4M |
| Q1 2026 | -$9.6M | -$3.6M |
| Q4 2025 | -$10.5M | -$3.5M |
| Q3 2025 | -$6M | -$1.3M |
| Q2 2025 | -$7.3M | -$2.7M |
| Q1 2025 | -$6M | -$1.3M |
| Q4 2024 | -$7.1M | -$1.5M |
ATOS has burned cash in almost every quarter: −$35M over the past year, against −$26M the year before.
ATOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +1.1M shares |
| 1 year | +16% | +1.4M shares |
| 3 years | +19% | +1.6M shares |
| 5 years | +23% | +1.9M shares |
| Available history | +1664% | +9.4M shares |
ATOS has 10M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
ATOS Net Leverage
ATOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ATOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 20.0 | Oversold |
ATOS's weekly RSI is 35 (neutral) and its Stochastic is 20 (oversold).
ATOS PE vs Healthcare Sector
ATOS has no meaningful PE right now: it lost money over the past year.
ATOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.30 | 16% below |
| 20 week MA | $2.35 | 17% below |
| 50 week MA | $4.70 | 59% below |
| 100 week MA | $8.59 | 77% below |
| 200 week MA | $12.2 | 84% below |
ATOS is in a downtrend: it's below all five of its weekly moving averages, and 84% below its 200-week average.
ATOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.1 | $13.2 | -47% |
| 2021 | $13.2 | $27.0 | +105% |
| 2022 | $27.0 | $8.70 | -68% |
| 2023 | $8.70 | $13.2 | +52% |
| 2024 | $13.2 | $14.7 | +12% |
| 2025 | $14.7 | $9.88 | -33% |
| 2026 YTD | $9.88 | $1.94 | -80% |
ATOS's yearly returns have swung widely, from +105% in 2021 to −68% in 2022. It's down 80% so far in 2026.